101 AI And Automation Are Empowering Drug Discovery The implementation of Artificial Intelligence/ Forecasted Reduction In Cost/Approval Attributable To AI/Automation Machine Learning (AI/ML) in the drug discovery $1,000 $900mm -$135mm process has increased the number of potential ) $900 M $800 -$45mm -$280mm active compounds that drug developers can t M $700 AI-Enabled $ os( Automated $600 Library Y C l screen from virtual and physical libraries. Screening Preclinical G e $500 Approval $440mm O g ova Workflows a r Cost L r p $400 O Ap Savings From Ave $300 Probability Of Precision HN High-throughput automated workflows like r Therapy C Pe $200 Approval Approval E Improvement T drug microsynthesis and in-vitro/in-vivo assays $100 Cost D $0 N are critical to leveraging AI-enabled drug A S L discovery. O O Forecasted Probability Forecasted Cost Per Approval T C Within the next decade, companies 30% Of Clinical Success $1,000 MI O 25% I implementing AI/ML drug discovery methods ($MM)$800 T 0.5x L 20% 2.1x MU and automated workflows are likely to double $600 their probability of clinical success from Phase 1 15% Percent10% $400 to approval. Earlier in the process, eliminating $200 compounds and increasing productivity should 5% 0% Cost/Drug Approval $0 cut the cost of a single drug approval in half. Legacy Precision Legacy Precision Sources: ARK Investment Management LLC, 2024. This ARK analysis is based on a range of external sources, including Recursion 2024, , Paul et al. 2010, Schreiber 2022, and Dreiman 2021, which may be provided upon request. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.